Behind the Scenes of Pfizer's Latest Options Trends

Investors with a lot of money to spend have taken a bearish stance on Pfizer PFE.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 15 uncommon options trades for Pfizer.

This isn't normal.

The overall sentiment of these big-money traders is split between 20% bullish and 80%, bearish.

Out of all of the special options we uncovered, 8 are puts, for a total amount of $352,200, and 7 are calls, for a total amount of $467,348.

Expected Price Movements

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $50.0 for Pfizer over the last 3 months.

Insights into Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $20.0 to $50.0, over the past month.

Pfizer Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Pfizer's Current Market Status

• With a trading volume of 10,536,136, the price of PFE is down by -0.02%, reaching $29.91.
• Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
• Next earnings report is scheduled for 71 days from now.

Professional Analyst Ratings for Pfizer

In the last month, 3 experts released ratings on this stock with an average target price of $48.666666666666664.

• An analyst from Barclays persists with their Equal-Weight rating on Pfizer, maintaining a target price of $34.
• An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $75.
• An analyst from Morgan Stanley persists with their Equal-Weight rating on Pfizer, maintaining a target price of $37.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.